Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Thursday. They currently have a $86.00 price objective on the stock. Needham & Company LLC’s target price points to a potential upside of 38.46% from the company’s previous close.

The analysts wrote, “Neurocrine reported 3Q17 financial results yesterday. Ingrezza 3Q17 sales were $45.8M, well above our $20.0M and consensus $11M ests. Mgmt noted growth in TRX from 745 in 2Q17 to 5100 in 3Q17. We are raising our near-term and long-term sales ests significantly. Our 4Q17 Ingrezza sales estimate is $55.0M (was $15.0M). Mgmt highlighted possible challenges in 4Q17, including new competitor Austedo and essentially a reduction in price w/ introduction of 80mg capsule. Nevertheless, we believe our ests may still be conservative. Our new $86 price target (was $58) is 25x our $4.72 2020 EPS est, disc 15% annually.””

A number of other equities research analysts have also recently weighed in on NBIX. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, July 5th. BMO Capital Markets lifted their price objective on Neurocrine Biosciences from $75.00 to $84.00 and gave the company an “outperform” rating in a research note on Friday, August 4th. Cowen and Company reaffirmed an “outperform” rating and issued a $65.00 price objective (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research note on Thursday, August 24th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $77.75.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same period in the previous year, the firm posted ($0.43) earnings per share.

TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Receives “Buy” Rating from Needham & Company LLC” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/11/02/neurocrine-biosciences-inc-nbix-receives-buy-rating-from-needham-company-llc.html.

In other news, insider Dimitri E. Grigoriadis sold 15,354 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $55.00, for a total value of $844,470.00. Following the completion of the sale, the insider now directly owns 123,045 shares of the company’s stock, valued at approximately $6,767,475. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $61.04, for a total value of $422,702.00. Following the completion of the sale, the insider now directly owns 55,898 shares of the company’s stock, valued at $3,412,013.92. The disclosure for this sale can be found here. Insiders sold a total of 123,846 shares of company stock valued at $7,004,150 over the last three months. Company insiders own 4.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after purchasing an additional 193 shares during the last quarter. ARS Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $207,000. Stephens Inc. AR purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at about $207,000. Crossmark Global Holdings Inc. purchased a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $286,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Neurocrine Biosciences in the 3rd quarter valued at about $305,000.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.